KPV
Clinician-prescribed. Ships from a licensed U.S. pharmacy.
Compounded KPV is a tripeptide derived from alpha-MSH. It interrupts the NF-kB inflammatory pathway inside the cell, with documented effects on gut and skin inflammation in preclinical research.
Inflammation has one main switch. KPV is small enough to reach it.
Most chronic inflammation runs through one transcription factor, NF-kB. KPV is transported into cells by PepT1, then blocks NF-kB nuclear translocation. Without NF-kB in the nucleus, transcription of TNF-alpha, IL-1, IL-6, and COX-2 drops. The result is a targeted reduction in cytokine output at the cellular level, documented in gut, skin, and immune cell lines. KPV comes from alpha-MSH, the hormone that tells skin to make pigment, but it leaves that job behind. In animals whose pigment receptor did not work at all, KPV still reduced inflammation. The anti-inflammatory effect runs on a separate track from anything that changes your skin tone.
The Evidence
All of this is laboratory and animal research. Human trials are still limited, and none of these results were produced in people. Talk with your provider about whether KPV fits your case.
A gut that stops flaring. Skin that stops reacting.
Patients on a KPV protocol typically report changes in two domains: gut comfort and skin reactivity. The shift is gradual over the first weeks, with most of the observed effect arriving by the end of the course. There is no stimulant effect and nothing to feel acutely. KPV works by lowering how much inflammatory protein the cell transcribes in the first place, which is slower and more specific than blanket immune suppression.
Oral Anti-Inflammatories vs. KPV
| Oral Anti-Inflammatories | KPV |
|---|---|
| A pill every day, often for years | One injection a day, on a defined course |
| Suppresses the whole immune system | Targets one inflammatory pathway |
| Hard on the stomach, liver, and kidneys | Well tolerated in published research |
| Hits many pathways at once | Works before the inflammatory proteins are made |
| No defined start or finish | A set course with a built-in break |
Topical Steroids vs. KPV
| Topical Steroids | KPV |
|---|---|
| Thins the skin with long-term use | Works inside the skin cell rather than on top of it |
| Stops working as well over time | No loss of response documented in published research |
| Treats the surface only | Lowers the inflammatory proteins the skin is producing |
| Can only be used on one spot for so long | Runs as a defined course with a break |
Details
Compounded KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), prepared as a 10 mg/ml sterile solution by a licensed 503A/503B compounding pharmacy.
KPV enters cells through the PepT1 di/tripeptide transporter, then blocks NF-kB nuclear translocation. The downstream effect is a reduction in transcription of TNF-alpha, IL-1, IL-6, and other pro-inflammatory cytokines.
Published preclinical research documents activity in intestinal epithelial cells, immune cells, and skin keratinocytes.
KPV is given by daily subcutaneous injection as a defined course, with your provider setting the schedule. Prescribed under an async telehealth model after intake review.
- Acts on NF-kB, the master switch behind most chronic inflammation
- Lowers the inflammatory proteins your cells release, including TNF-alpha, IL-1, and IL-6, in published research
- Researched in both gut and skin, the two places patients report change
- Inflamed tissue pulls KPV in faster, so it concentrates where it is needed
- Well tolerated across published research, without broadly suppressing immunity
- Compounded by a licensed 503A/503B pharmacy, prescribed through async telehealth
Administer by subcutaneous injection into the abdomen, rotating injection sites with each dose to help minimize skin irritation.
Do not inject into areas that are bruised, tender, red, firm, scarred, or otherwise irritated.
Follow the dosing instructions provided by your prescribing provider. Do not increase, decrease, skip, or repeat a dose unless directed by your provider.
If you miss a dose or have questions, contact your prescribing provider for guidance.
Full protocol detail, including how to measure and store each dose, is on the KPV dosing page.
Most commonly reported in published research and clinical case series: injection-site redness, transient itching, mild fatigue, and headache. Antibody formation is theoretically possible with any peptide, though it is not commonly reported with KPV.
Do not use KPV if you have an active malignancy under treatment, are pregnant or breastfeeding, or have a known hypersensitivity to alpha-MSH-derived peptides.
Discuss any autoimmune diagnosis with your provider before starting.
Stop use and contact your provider if you experience persistent rash, swelling, or signs of allergic reaction.
Disclaimer and Transparency
Important Information About Compounded Injectables
- Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
- IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
- Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.
All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.
*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.
Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.
KPV FAQ
What is KPV?
How does KPV work?
What does the protocol look like?
Is KPV FDA-approved?
What does the research actually show?
Is KPV the same as alpha-MSH or Melanotan?
KLOW already contains KPV. Why run it on its own?
What if I miss a dose?
How do I store the vial?
Who should not take KPV?
What happens next
Choose Your Protocol
No consultation fee. No hidden costs. No subscription.
Complete Your Clinical Intake
A board-certified clinician reviews your health history, medications, and goals. Asynchronous. No appointments. No waiting rooms.
Your Prescription Ships
Compounded by a licensed U.S. pharmacy. Delivered to your door in 2-4 business days. Cold-shipped when required.
Stack Your Protocol
KLOW
KLOW is a four-peptide blend that already includes KPV alongside GHK-Cu, BPC-157, and TB-500. Patients running a standalone KPV cycle often transition to KLOW for a broader recovery and skin protocol.
GHK-CU
GHK-Cu is the copper tripeptide with the longest clinical record in skin repair, driving collagen synthesis and barrier recovery. Patients pair it with KPV when skin reactivity is the target, so tissue rebuilds while the inflammatory load stays controlled.
Target where the inflammation starts.
KPV is prescribed via async telehealth after a clinical intake review, compounded by a licensed 503A/503B pharmacy, and shipped direct. Your provider sets your course during intake.
Compounded medications are not FDA-approved. Statements on this page reference published preclinical and mechanistic research; not all findings have been replicated in human clinical trials. This is not medical advice. Eligibility for KPV is determined by your provider through the IVUSE+ telehealth intake. Pregnant or breastfeeding patients, patients with active malignancy under treatment, and patients with known hypersensitivity to alpha-MSH-derived peptides should not use KPV.
